Any current/future new fundraising through debt or equity?

There are no specific mentions of any current or planned fundraising through debt or equity in the provided transcript. The company focuses on growing its business primarily through internal cash generation. The export business, though growing, is profitable and does not require major capital allocation. Management prefers to focus on operational efficiency, R&D, and minor geographical expansions rather than large-scale capital raises. No guidance or forward-looking statements on fundraising were given, reflecting a cautious approach. The company is not planning any major expansion in division

Any current/future capex/capital investment/strategic investment?

Ongoing capex includes construction of a new corporate office and R&D center, expected to complete by end of calendar year 2024, with expenditures spilling over into FY25. Regular maintenance capex is around INR 50 crores annually. Total capex for the next 12-15 months is approximately INR 170 crores, covering corporate office, manufacturing site projects, and smaller ongoing initiatives. No major new R&D capital expenditure planned; focus is on revenue expenditure like clinical studies and regulatory filings, primarily for export markets (especially the US). The company continues to i

Future growth expectations in sales/revenue/volumes?

Domestic business growth is expected to continue with focus on volume, price, and new product mix, despite recent volume stagnation; price growth was 4.9% and new product growth 0.8% in H1 FY24. Export business shows strong momentum with 25% Y-o-Y growth, reaching INR400 crores run rate; expected to grow further with increasing geographic spread. No aggressive expansion of MR (Medical Representative) force planned; focus is on improving MR productivity and consolidating existing field force of ~4,800. Growth drivers include expansion into weaker geographies like East and South India, alo

Future growth expectations in earnings/operating earnings/profits/EPS?

Management refrains from giving specific forward-looking guidance on margins or earnings due to market dynamics and uncertainties (Page 8). The focus remains on growing the business top-line along with profitability, maintaining growth momentum (Page 8). Export business is growing healthily at a double-digit rate, signaling promising future potential (Page 3, 19). Domestic business growth was muted in H1 FY24 (~6%), with volume stagnation, but price increases and new product introductions contribute positively (Page 4). Marketing and sales force expansion has paused, with an emphasis on improv

Current/ Expected Orderbook/ Pending Orders?

The transcript from the provided pages does not mention or provide information about the current or expected order book or pending orders for the company. The discussion mainly revolves around business segments, profitability, capex, market strategies, field force, product categories, and financial performance, but no specific details on order book or pending orders were disclosed.

FDCQ2 FY24Pharmaceuticals & Biotechnology

FDC Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹377P/E: 19.9Market Cap: ₹6.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Domestic business growth is expected to continue with focus on volume, price, and new product mix, despite recent volume stagnation; price growth was 4.9% and new product growth 0.8% in H1 FY24.
Export business shows strong momentum with 25% Y-o-Y growth, reaching INR400 crores run rate; expected to grow further with increasing geographic spread.
No aggressive expansion of MR (Medical Representative) force planned; focus is on improving MR productivity and consolidating existing field force of ~4,800.
Growth drivers include expansion into weaker geographies like East and South India, along with strengthening top brands beyond INR100 crore mark.
Growth rate for FDC outpaced industry with 14.5% vs. market growth around 9-10% in recent months.
Corporate office and R&D investments ongoing, with capex of ~INR170 crore planned over 12–15 months, supporting future growth infrastructure.
Management focused on balanced growth with profitability, without giving specific forward-looking margin or growth guidance due to market dynamics.

Margin guidance

Category 3

Management refrains from giving specific forward-looking guidance on margins or earnings due to market dynamics and uncertainties (Page 8).
The focus remains on growing the business top-line along with profitability, maintaining growth momentum (Page 8).
Export business is growing healthily at a double-digit rate, signaling promising future potential (Page 3, 19).
Domestic business growth was muted in H1 FY24 (~6%), with volume stagnation, but price increases and new product introductions contribute positively (Page 4).
Marketing and sales force expansion has paused, with an emphasis on improving MR productivity and consolidating existing operations before future growth (Pages 11-13).
Capex in next 12-15 months planned at ~INR170 crores, including investments in corporate office and R&D, supporting future infrastructure (Page 18).
Given market volatility, no explicit EPS or profit growth targets were set publicly; growth expected through both domestic consolidation and export expansion (Pages 8, 19).

See what FDC management said on margin guidance — free account, 30 seconds.

Fundraise plans

There are no specific mentions of any current or planned fundraising through debt or equity in the provided transcript.
The company focuses on growing its business primarily through internal cash generation.
The export business, though growing, is profitable and does not require major capital allocation.
Management prefers to focus on operational efficiency, R&D, and minor geographical expansions rather than large-scale capital raises.
No guidance or forward-looking statements on fundraising were given, reflecting a cautious approach.
The company is not planning any major expansion in divisional salesforce or major capex presently.
Management emphasis is on investing in existing business areas and maintaining profitability rather than seeking external funding.

See what FDC management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing capex includes construction of a new corporate office and R&D center, expected to complete by end of calendar year 2024, with expenditures spilling over into FY25.
Regular maintenance capex is around INR 50 crores annually.
Total capex for the next 12-15 months is approximately INR 170 crores, covering corporate office, manufacturing site projects, and smaller ongoing initiatives.
No major new R&D capital expenditure planned; focus is on revenue expenditure like clinical studies and regulatory filings, primarily for export markets (especially the US).
The company continues to invest in export business growth and infrastructure but refrains from cross-capital allocation between domestic and export segments.
Minor geographical expansions, especially in eastern India, are ongoing but no major salesforce expansion planned in near term.

Track FDC — get its next earnings analysis in your feed

How does FDC rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisFDC

Rev 3Mar 3

See where FDC sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does FDC rank in Pharmaceuticals & Biotechnology?

Compare FDC against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What FDC's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

FDC Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does FDC rank in Pharmaceuticals & Biotechnology?

Continue your research

What FDC's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season